(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2015 (15.10.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/157252 A1

(51) International Patent Classification:
*C12N 5/0783* (2010.01) *A61K 31/00* (2006.01)
*A61K 35/17* (2015.01) *A61P 35/02* (2006.01)

(21) International Application Number:
PCT/US2015/024671

(22) International Filing Date:
7 April 2015 (07.04.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 61/976,396 | 7 April 2014 (07.04.2014) | US |
| 62/007,309 | 3 June 2014 (03.06.2014) | US |
| 62/036,493 | 12 August 2014 (12.08.2014) | US |
| 62/076,238 | 6 November 2014 (06.11.2014) | US |
| 62/087,888 | 5 December 2014 (05.12.2014) | US |
| 62/097,278 | 29 December 2014 (29.12.2014) | US |


(71) Applicant: **BROGDON, Jennifer** [US/US]; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US).

(72) Inventors; and
(71) Applicants : **BYRD, John** [US/US]; 1950 Arlington Avenue, Columbus, OH 43212 (US). **DUBOVSKY, Jason** [US/US]; 1040 Larkstone Drive, Columbus, OH 43235 (US). **FRAIETTA, Joseph** [US/US]; 18 Saddle Lane, Cherry Hill, NJ 08002 (US). **GILL, Saar** [US/US]; 30 North 3rd Street, Apt. 4A, Philadelphia, PA 19106 (US). **GLASS, David** [US/US]; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **JOHNSON, Amy** [US/US]; 5696 Winters Run Road, Dublin, OH 43016 (US). **JUNE, Carl, H.** [US/US]; 409 Baird Road, Merion Station, PA 19066 (US). **KENDERIAN, Saad** [US/US]; 103 Surgeon Generals Ct, Philadelphia, PA 19146 (US). **MANNICK, Joan** [US/US]; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **MAUS, Marcela** [US/US]; 705 Haviland Drive, Bryn Mawr, PA 19010 (US). **MURPHY, Leon** [US/US]; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **MUTHUSAMY, Natarajan** [US/US]; 6129 Glenworth Court, Galloway, OH 43119 (US). **PORTER, David, L.** [—/US]; 821 Crum Creek Road, Springfield, PA 19064 (US). **RUELLA, Marco** [IT/US]; 500 S. 47th Street, Apt.207, Philadelphia, PA 19143 (US). **SELLERS, William, Raj** [—/US]; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **WASIK, Mariusz** [US/US]; 210 Cedarbrook Road, Ardmore, PA 19003 (US).

(74) Agent: **COLLAZO, Diana, M.**; Lando & Anastasi LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

*[Continued on next page]*

(54) Title: TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR





FIG. 60

(57) Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

WO 2015/157252 A1

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

**(84) Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*